ArticleJACC. Advances2026
Assessing Coronary Calcium Thresholds on Attenuation-Correction CT With Myocardial Perfusion Imaging Equating to Secondary Prevention.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatients with a coronary artery calcium (CAC) score >300 on dedicated CAC scoring computed tomography (CT) are at equivalent risk of major adverse cardiac events (MACE) as those with established atherosclerotic cardiovascular disease (ASCVD).
objectivesThe aim of the study was to identify the extent of CAC on CT performed for attenuation correction (CTAC) as part of nuclear myocardial perfusion imaging that equates to secondary prevention.
methodsWe retrospectively studied 17,901 patients (48% female, age 64 ± 12 years, body mass index 30 kg/m2 [26-36]) who underwent nuclear myocardial perfusion imaging with CTAC (single photon emission computed tomography/CT or positron emission tomography/CT) at a single center. Prior ASCVD was defined as myocardial infarction (MI), cerebrovascular accident, peripheral artery disease, or prior revascularization. A semiquantitative visually estimated CAC score was obtained by scoring CAC in each coronary artery from 0 (absent) to 3 (severe), yielding a total score of 0 to 12 (zero, mild 1-2, moderate 3-6, and severe ≥7). The primary outcome was the composite of death, MI, or late revascularization.
resultsAmong 13,852 patients without prior ASCVD (CAC zero 45%, mild 23%, moderate 21%, severe 11%) and 4,049 with ASCVD, 2,006 patients (11%) experienced MACE during a median follow-up of 25 (Q1-Q3: 10-43) months. In multivariable Cox regression, patients with severe calcification had no difference in risk for MACE, MI, or all-cause mortality vs ASCVD patients (P > 0.05).
conclusionsPatients without prior ASCVD but with severe CAC (score ≥7) on CTAC demonstrated a risk for cardiovascular events and mortality comparable to those with known ASCVD, highlighting the need for more aggressive management in this high-risk primary prevention group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.